Robert Cerwinski

Rob Cerwinski, managing partner, is a seasoned patent litigator and IP strategist with 20+ years of experience at premier U.S. law firms helping international clients launch biopharma products into the highly-competitive U.S. market.

Mr. Cerwinski specializes in helping companies devise cost-effective strategies to navigate the complex and intertwined legal, regulatory and financial hurdles that can delay or prevent product launch. His successes in pre-litigation strategy and in the courtroom have driven the launch of 20+ biopharma products in the U.S. and Europe.

Mr. Cerwinski holds a Master of Science Degree in molecular biology and has a deep understanding of the science, business and regulation of biopharma product development, manufacture and marketing.

Mr. Cerwinski co-founded the industry-leading biosimilars practice at Goodwin Procter LLP and is a recognized global authority on biosimilars. He is Senior Editor of the leading legal treatise in the field, Guide to Biosimilars Litigation and Regulation in the U.S. (published by Thomson-Reuters) and founded Goodwin’s award-winning biosimilars blog, Big Molecule Watch and its companion blog, Big Molecule Watch China.

Prior to forming Gemini, Mr. Cerwinski was a partner at Goodwin Procter LLP in New York City. Before joining Goodwin in 2014, Mr. Cerwinski was a partner at Kenyon & Kenyon LLP. Before pursuing a career in law, he worked for a major Japanese pharmaceutical company in Tokyo assisting with intellectual property matters concerning biotechnology products.

Mr. Cerwinski has been interviewed extensively by Dow Jones, Forbes, the Center for Biosimilars, Bloomberg, SCRIPS, The Pink Sheet, and other publications. Thought leadership highlights include:

Speaker, “Top of Mind Issues for Global Life Sciences Companies in the Era of COVID-19,” Goodwin Webinar, April 2020

Co-author, “INSIGHT: Why the Illegality Doctrine Shouldn’t Apply to Cannabis Patents”, Bloomberg Law, January 2020

Speaker, “Goodwin Lawyers Give a Look at Biosimilar Litigation,” Not So Different: A Podcast from the Center for Biosimilars, January 2020

Senior Editor, Guide to Biosimilars Litigation and Regulation in the U.S., published by Thomson Reuters, November 2019

Co-author, “Protect At All Costs: How the Maker of the World’s Bestselling Drug Keeps Prices Sky-High”, Fortune, July 2019

“The US’s First All Biosimilar Patent Suit Shows New Pharma IP Landscape is Emerging,” IAM Global, February 2019

Speaker, “Current Infliximab Litigation,” The Center for Biosimilars, September 2017

Speaker, “Recent Trends in PTAB Decisions on Biologics, Biosimilars,” The Center for Biosimilars, September 2017

Speaker, “The Potential for an Executive Order on Drug Pricing,” The Center for Biosimilars, September 2017

Speaker, “Shall we Dance: Mastering the “Steps” of the BPCIA While Avoiding Common Pitfalls,” American Conference Institute 8th Annual Biosimilars Summit, June 2017

Speaker, “Biosimilar Investment Landscape in 2017,” Goodwin Seminar, January 2017

Speaker, “Biosimilars: Annual Market Review,” Goodwin Seminar, January 2016

Speaker, “Analysis of Amgen v. Sandoz Federal Circuit Decision,” Goodwin Webinar, August 2015

Speaker, “Declining to Dance? Lessons Learned from Early BPCIA Cases on Whether the Pathway is Mandatory” American Conference Institute 6thAnnual Biosimilars Summit, June 2015

Co-author, “Order in Amgen v. Sandoz Provides First Judicial Interpretations of the BPCIA Patent Dispute Resolution Provisions,” Goodwin Alert, March 2015

Speaker, “Understanding Biosimilars: Intellectual Property Challenges,” Goodwin Seminar, January 2015